OncoMatch/Clinical Trials/NCT05430698
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
Is NCT05430698 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies PD-1antibody plus GEMOX for perihilar cholangiocarcinoma.
Treatment: PD-1antibody plus GEMOX — This is an open-label,single center,non-randomized,single arm exploratory study. The objective of this study is to evaluate the efficacy and safety of PD-1 antibody plus GEMOX as postoperative adjuvant therapy in perihilar cholangiocarcinoma with positively metastatic lymph nodes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: gemcitabine-based chemotherapy
Have used gemcitabine-based chemotherapy within 6 months
Cannot have received: anti-PD-1 therapy
have used PD-1 monoclonal antibody ... within 6 months
Cannot have received: anti-PD-L1 therapy
have used ... PD-L1 monoclonal antibody treatment within 6 months
Lab requirements
Blood counts
Neutrophils ≥ 1.5*10^9/L; platelets ≥ 100*10^9/L; hemoglobin ≥ 9g/dl; serum albumin ≥ 3g/dl
Kidney function
Serum creatinine ≤ 1.5 times the upper limit of normal, and creatinine clearance ≥ 60ml/min (Cockcroft-Gault formula)
Liver function
Bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 3 times the upper limit of normal; Child-Pugh score A period
The functional indicators of important organs meet the following requirements ... Child-Pugh score A period
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify